Healthcare

  • Palcohol powdered alcohol condemned by public health advocates as company seeks US approval ABC - 2 hours 31 minutes ago

    A company is seeking approval to sell powdered alcohol in the United States, sparking alarm from alcohol policy researchers. The company, Palcohol, says it wants to make its product, including powdered vodka and rum, accessible to consumers wherever they go. Powdered alcohol is or has been available in Germany, Holland and Japan and the technology behind it is over 40 years old. The plan to sell it in the US has alarmed public health advocates, who fear powdered alcohol could be abused or easily smuggled inside public venues.

  • Investor pressure pushing drugmaker M&A AAP - 8 hours ago

    Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry. Swiss drugmaker Novartis AG says it's trading its vaccine business for GlaxoSmithKline Plc's cancer drug business and selling its veterinary drug business to Eli Lilly and Co. Meanwhile, Canadian drugmaker Valeant Pharmaceuticals International Inc says it has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $US45 billion ($A48.20 billion). Amid easier financing and low interest rates, four smaller drugmakers also have announced bids of $US3 billion or more to acquire competitors since January, according to data and research firm The Mergermarket Group.

  • Amgen misses 1Q views as higher costs cut profit Associated Press - 10 hours ago
    Amgen misses 1Q views as higher costs cut profit

    Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply. Last year's quarter also gained from a tax benefit. The company missed ...

  • Investor pressure pushing drugmaker M&A deals Associated Press - 10 hours ago
    Investor pressure pushing drugmaker M&A deals

    Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could ...

  • Gilead says 1Q sales of Sovaldi totaled $2.27B Associated Press - 11 hours ago

    Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi totaled more than $2 billion in its first full quarter on the market, and it said quarterly net income tripled. The company reported ...

  • Final Glance: Medical Devices companies Associated Press - 11 hours ago

    Shares of some top medical devices companies were mixed at the close of trading: Allergan rose $21.65 or 15.2 percent, to $163.65. Baxter International Inc. fell $.77 or 1.1 percent, to $72.38. Boston ...

  • Final Glance: Pharmaceuticals companies Associated Press - 11 hours ago

    Shares of some top pharmaceuticals companies were mixed at the close of trading: Baxter International Inc. fell $.77 or 1.1 percent, to $72.38. Bristol-Myers Squibb Co. rose $.48 or 1.0 percent, to $50.99. ...

  • Final Glance: Health Care Equipment companies Associated Press - 11 hours ago

    Shares of some top health care equipment companies were mixed at the close of trading: Becton, Dickinson & Co. rose $.06 or .1 percent, to $114.19. Covidien fell $.08 or .1 percent, to $70.59. Patterson ...

  • Final Glance: Drug Benefits companies Associated Press - 11 hours ago

    Shares of some top drug benefits companies were down at the close of trading: CVSCaremark fell $.43 or .6 percent, to $73.24. Express Scripts Holding Co. fell $.37 or .5 percent, to $70.96.

  • Final Glance: Biotechnology companies Associated Press - 11 hours ago

    Shares of some top biotechnology companies were up at the close of trading: Amgen Inc. rose $2.28 or 1.9 percent, to $119.30. Biogen Idec rose $8.22 or 2.8 percent, to $306.20. Celgene Corp. rose $2.81 ...

  • Gilead Sales Double on $1,000 Hepatitis C Pills BusinessWeek - 11 hours ago

    Sovaldi sales soared in the first quarter for Gilead Sciences despite criticism over the high cost of the new therapy

  • The Novartis-Glaxo-Lilly Swap’s Downside: Less Research BusinessWeek - 12 hours ago

    GlaxoSmithKline and Novartis will form a consumer-health joint venture, while Eli Lilly is purchasing Novartis’s animal-health unit

  • FDA panel rejects combination pain pill Associated Press - 14 hours ago

    Federal health advisers have unanimously rejected an experimental pain pill that combines two common opioids, oxycodone and morphine. The combination pill, Moxduo, was developed by QRxPharma with the aim ...

  • Midday Glance: Pharmaceuticals companies Associated Press - 16 hours ago

    Shares of some top pharmaceuticals companies are mixed at 1 p.m.: Baxter International Inc. fell $.44 or .6 percent, to $72.71. Bristol-Myers Squibb Co. rose $.79 or 1.6 percent, to $51.30. Hospira rose ...

  • Midday Glance: Health Care Equipment companies Associated Press - 16 hours ago

    Shares of some top health care equipment companies are mixed at 1 p.m.: Becton, Dickinson & Co. rose $.37 or .3 percent, to $114.50. Covidien plc fell $.12 or .2 percent, to $70.55. Patterson rose $.18 ...

  • Midday Glance: Medical Devices companies Associated Press - 16 hours ago

    Shares of some top medical devices companies are mixed at 1 p.m.: Allergan rose $21.98 or 15.5 percent, to $163.98. Baxter International Inc. fell $.44 or .6 percent, to $72.71. Boston Scientific Corp. ...

  • Midday Glance: Drug Benefits companies Associated Press - 16 hours ago

    Shares of some top drug benefits companies are mixed at 1 p.m.: CVSCaremark fell $.13 or .2 percent, to $73.54. Express Scripts Holding Co. rose $.32 or .4 percent, to $71.65.

  • Midday Glance: Biotechnology companies Associated Press - 16 hours ago

    Shares of some top biotechnology companies are up at 1 p.m.: Amgen Inc. rose $2.62 or 2.2 percent, to $119.64. Biogen Idec rose $9.75 or 3.3 percent, to $307.73. Celgene Corp. rose $3.00 or 2.1 percent, ...

  • Novartis reshapes business with GSK, Lilly deals Associated Press - 17 hours ago
    Novartis reshapes business with GSK, Lilly deals

    Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. ...

  • FDA plan would speed up medical device approvals Associated Press - 18 hours ago

    The Food and Drug Administration unveiled a proposal Tuesday designed to speed up development and approval of medical devices that treat life-threatening diseases and debilitating conditions. Under the ...

  • Early Glance: Pharmaceuticals companies Associated Press - 19 hours ago

    Shares of some top pharmaceuticals companies are mixed at 10 a.m.: Baxter International Inc. rose $.06 or .1 percent, to $73.21. Bristol-Myers Squibb Co. rose $.64 or 1.3 percent, to $51.15. Hospira rose ...

  • Early Glance: Medical Devices companies Associated Press - 19 hours ago

    Shares of some top medical devices companies are mixed at 10 a.m.: Allergan rose $21.94 or 15.5 percent, to $163.94. Baxter International Inc. rose $.06 or .1 percent, to $73.21. Boston Scientific Corp. ...

  • Early Glance: Health Care Equipment companies Associated Press - 19 hours ago

    Shares of some top health care equipment companies are mixed at 10 a.m.: Becton, Dickinson & Co. rose $.54 or .5 percent, to $114.67. Covidien plc fell $.04 or percent, to $70.64. Patterson rose $.18 or ...

  • Early Glance: Drug Benefits companies Associated Press - 19 hours ago

    Shares of some top drug benefits companies are up at 10 a.m.: CVSCaremark unchanged at $73.67. Express Scripts Holding Co. rose $.09 or .1 percent, to $71.42.

  • Early Glance: Biotechnology companies Associated Press - 19 hours ago

    Shares of some top biotechnology companies are up at 10 a.m.: Amgen Inc. rose $1.10 or .9 percent, to $118.12. Biogen Idec rose $7.44 or 2.5 percent, to $305.42. Celgene Corp. rose $1.41 or 1.0 percent, ...

  • Novartis reshapes business with GSK, Lilly dealshe Associated Press - 20 hours ago
    Novartis reshapes business with GSK, Lilly dealshe

    Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. ...

  • Ahead of the Bell: Shares of drugmaker Lilly slip Associated Press - 20 hours ago

    Eli Lilly and Co. received a key regulatory approval for a new cancer treatment Monday evening, but the drugmaker's shares slipped in premarket trading Tuesday after Lilly also announced a $5.4 billion ...

  • Early movers: CMCSA, NFLX, GM, PFE, NVS & more CNBC - 21 hours ago
    Early movers: CMCSA, NFLX, GM, PFE, NVS & more

    These are the stocks posting the largest moves before the bell.

  • Novartis, GSK, Lilly in multibillion-dollar deals Associated Press - Tue, Apr 22, 2014 6:05 PM AEST

    Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting ...

  • Huge pharma sector manoeuvres boost European stocks AFP - Tue, Apr 22, 2014 4:52 PM AEST
    Huge pharma sector manoeuvres boost European stocks

    Huge deal-making in the pharmaceutical sector gave European stocks a shot in the arm on Tuesday, even though tension over the crisis in Ukraine lurked in the background, traders said. Shares in European pharmaceutical groups surged owing to a major reshaping of the sector, driven by Novartis of Switzerland and GlaxoSmithKline in London. London's FTSE 100 gained 0.85 percent to 6,681.76 points compared to Thursday's closing level -- the last trading day before European markets closed for Easter. Wall Street was also firm, with the Dow Jones main index showing a gain of 0.59 percent and the Nasdaq index advancing 0.92 percent.

  • Shake-up in pharma world as Novartis, GSK announce mega-deals AFP - Tue, Apr 22, 2014 4:31 PM AEST
    Shake-up in pharma world as Novartis, GSK announce mega-deals

    Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, unveiling multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures by the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector, GSK boost its share in vaccines and Eli Lilly strengthen its animal health unit. In the biggest of the deals announced Thursday, Novartis said it plans to buy GSK's oncology (cancer treatment) business for $16 billion (11.5 billion euros) in cash, including $1.5 billion that would depend on future performance. The two groups further announced a joint venture to create "a world-leading consumer healthcare business," focused on wellness, oral health, nutrition and skin health and expected to book around $10 billion in annual sales.

  • Novartis revamps pharma world with mega-deals with GSK, Eli Lilly AFP - Tue, Apr 22, 2014 2:24 PM AEST
    Novartis revamps pharma world with mega-deals with GSK, Eli Lilly

    Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, revealing multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures involving the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector and GSK seizing the chance to boost its share in vaccines. "These transactions mark a transformational moment for Novartis," chief executive Joseph Jimenez said in the statement, adding that the deals would help give the Swiss company a sharper focus. Market observers also hailed the deals, which mark one of the biggest shake-ups at Novartis since its creation in a 1996 merger nearly two decades ago and which comes as the global pharmaceutical industry struggles to deal with cuts in government healthcare spending around the world.

  • Botox maker Allergan draws bid from Valeant Associated Press - Tue, Apr 22, 2014 2:03 PM AEST

    Valeant Pharmaceuticals is teaming up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion. Valeant said Monday that it intends to propose a merger ...

  • European stocks rise on pharmaceutical shake-up AFP - Tue, Apr 22, 2014 10:14 AM AEST
    European stocks rise on pharmaceutical shake-up

    European stock markets rallied in morning deals on Tuesday as shares in pharmaceutical groups surged owing to a major reshaping of the sector. London's benchmark FTSE 100 index climbed 0.79 percent to 6,677.55 points compared with Thursday's closing level -- the last trading day before European markets closed for Easter. "The pharma sector stood out (Tuesday)... on the back of news that two of the biggest players in the sector are making major changes to their business models," said Farhan Ahmad, a trader at TradeNext. Swiss pharmaceutical giant Novartis and British group GlaxoSmithKline (GSK) announced a major shake-up of their healthcare divisions on Tuesday in deals worth billions of dollars.

  • Valeant to bid for Botox maker Allergan Associated Press - Tue, Apr 22, 2014 10:08 AM AEST

    Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion. Valeant said Monday that it intends to propose a merger ...